
Michael D. Burkhart
Examiner (ID: 12476, Phone: (571)272-2915 , Office: P/1633 )
| Most Active Art Unit | 1633 |
| Art Unit(s) | 1633, 1638, 1636 |
| Total Applications | 1138 |
| Issued Applications | 600 |
| Pending Applications | 126 |
| Abandoned Applications | 442 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17044944
[patent_doc_number] => 11098112
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-24
[patent_title] => Anti-VEGF protein compositions and methods for producing the same
[patent_app_type] => utility
[patent_app_number] => 16/996042
[patent_app_country] => US
[patent_app_date] => 2020-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 60
[patent_figures_cnt] => 86
[patent_no_of_words] => 67542
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16996042
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/996042 | Anti-VEGF protein compositions and methods for producing the same | Aug 17, 2020 | Issued |
Array
(
[id] => 16750156
[patent_doc_number] => 20210102165
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-08
[patent_title] => METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY
[patent_app_type] => utility
[patent_app_number] => 16/989686
[patent_app_country] => US
[patent_app_date] => 2020-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6728
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16989686
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/989686 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | Aug 9, 2020 | Abandoned |
Array
(
[id] => 16557190
[patent_doc_number] => 20210002338
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-07
[patent_title] => Cancer Treatment Methods Using Thermotherapy And/Or Enhanced Immunotherapy
[patent_app_type] => utility
[patent_app_number] => 16/988697
[patent_app_country] => US
[patent_app_date] => 2020-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58250
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 129
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16988697
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/988697 | Cancer Treatment Methods Using Thermotherapy And/Or Enhanced Immunotherapy | Aug 8, 2020 | Pending |
Array
(
[id] => 16720105
[patent_doc_number] => 20210087252
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-25
[patent_title] => Mutant IDH1 Specific T Cell Receptor
[patent_app_type] => utility
[patent_app_number] => 16/987835
[patent_app_country] => US
[patent_app_date] => 2020-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17785
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16987835
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/987835 | Mutant IDH1 Specific T Cell Receptor | Aug 6, 2020 | Abandoned |
Array
(
[id] => 16822714
[patent_doc_number] => 20210138007
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-13
[patent_title] => ONCOLYTIC HSV VECTOR
[patent_app_type] => utility
[patent_app_number] => 16/985459
[patent_app_country] => US
[patent_app_date] => 2020-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13138
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -47
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16985459
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/985459 | Oncolytic HSV vector | Aug 4, 2020 | Issued |
Array
(
[id] => 18478438
[patent_doc_number] => 11692169
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-04
[patent_title] => Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
[patent_app_type] => utility
[patent_app_number] => 16/939466
[patent_app_country] => US
[patent_app_date] => 2020-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 21
[patent_no_of_words] => 33244
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16939466
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/939466 | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells | Jul 26, 2020 | Issued |
Array
(
[id] => 20143973
[patent_doc_number] => 12378300
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-05
[patent_title] => Elimination of CD19-positive lymphoid malignancies by CD19-car expressing NK cells
[patent_app_type] => utility
[patent_app_number] => 16/934606
[patent_app_country] => US
[patent_app_date] => 2020-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 17
[patent_no_of_words] => 12004
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16934606
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/934606 | Elimination of CD19-positive lymphoid malignancies by CD19-car expressing NK cells | Jul 20, 2020 | Issued |
Array
(
[id] => 19521331
[patent_doc_number] => 12123043
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-22
[patent_title] => Methods and means for the production of Ig-like molecules
[patent_app_type] => utility
[patent_app_number] => 16/934925
[patent_app_country] => US
[patent_app_date] => 2020-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 39
[patent_figures_cnt] => 57
[patent_no_of_words] => 32080
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16934925
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/934925 | Methods and means for the production of Ig-like molecules | Jul 20, 2020 | Issued |
Array
(
[id] => 16727842
[patent_doc_number] => 20210094989
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-01
[patent_title] => Silk Proteins
[patent_app_type] => utility
[patent_app_number] => 16/931710
[patent_app_country] => US
[patent_app_date] => 2020-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25699
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16931710
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/931710 | Silk Proteins | Jul 16, 2020 | Abandoned |
Array
(
[id] => 16483963
[patent_doc_number] => 20200377564
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-03
[patent_title] => REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS
[patent_app_type] => utility
[patent_app_number] => 16/875591
[patent_app_country] => US
[patent_app_date] => 2020-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 78916
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16875591
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/875591 | Regulated synthetic gene expression systems | May 14, 2020 | Issued |
Array
(
[id] => 16541314
[patent_doc_number] => 20200407727
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-31
[patent_title] => GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT
[patent_app_type] => utility
[patent_app_number] => 16/858512
[patent_app_country] => US
[patent_app_date] => 2020-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26907
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16858512
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/858512 | Genome editing using effector oligonucleotides for therapeutic treatment | Apr 23, 2020 | Issued |
Array
(
[id] => 17541022
[patent_doc_number] => 11306133
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-19
[patent_title] => Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/858183
[patent_app_country] => US
[patent_app_date] => 2020-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 45
[patent_figures_cnt] => 46
[patent_no_of_words] => 30481
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16858183
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/858183 | Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof | Apr 23, 2020 | Issued |
Array
(
[id] => 17734711
[patent_doc_number] => 20220220170
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => AAV CAPSID CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/605615
[patent_app_country] => US
[patent_app_date] => 2020-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27146
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -37
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605615
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/605615 | AAV CAPSID CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | Apr 22, 2020 | Pending |
Array
(
[id] => 18398114
[patent_doc_number] => 11660229
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-30
[patent_title] => Cancer treatment methods using thermotherapy and/or enhanced immunotherapy
[patent_app_type] => utility
[patent_app_number] => 16/843831
[patent_app_country] => US
[patent_app_date] => 2020-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 67100
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 203
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16843831
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/843831 | Cancer treatment methods using thermotherapy and/or enhanced immunotherapy | Apr 7, 2020 | Issued |
Array
(
[id] => 16711893
[patent_doc_number] => 20210079040
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-18
[patent_title] => METHODS AND COMPOSITIONS FOR TREATMENT OF CARTILAGE AND DISC TISSUE PATHOLOGIES
[patent_app_type] => utility
[patent_app_number] => 16/841276
[patent_app_country] => US
[patent_app_date] => 2020-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27457
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841276
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/841276 | METHODS AND COMPOSITIONS FOR TREATMENT OF CARTILAGE AND DISC TISSUE PATHOLOGIES | Apr 5, 2020 | Abandoned |
Array
(
[id] => 16326812
[patent_doc_number] => 20200297777
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-24
[patent_title] => METHODS OF TRANSDIFFERENTIATION AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/836967
[patent_app_country] => US
[patent_app_date] => 2020-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36058
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 152
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16836967
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/836967 | Methods of transdifferentiation and methods of use thereof | Mar 31, 2020 | Issued |
Array
(
[id] => 16345126
[patent_doc_number] => 20200309776
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => HLA G-MODIFIED CELLS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 16/832321
[patent_app_country] => US
[patent_app_date] => 2020-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15438
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16832321
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/832321 | HLA G-MODIFIED CELLS AND METHODS | Mar 26, 2020 | Abandoned |
Array
(
[id] => 17748303
[patent_doc_number] => 20220226506
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => EXPRESSION CONSTRUCTS FOR THE GENETIC MODIFICATION OF CELLS
[patent_app_type] => utility
[patent_app_number] => 17/439921
[patent_app_country] => US
[patent_app_date] => 2020-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14361
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17439921
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/439921 | EXPRESSION CONSTRUCTS FOR THE GENETIC MODIFICATION OF CELLS | Mar 16, 2020 | Pending |
Array
(
[id] => 17748303
[patent_doc_number] => 20220226506
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => EXPRESSION CONSTRUCTS FOR THE GENETIC MODIFICATION OF CELLS
[patent_app_type] => utility
[patent_app_number] => 17/439921
[patent_app_country] => US
[patent_app_date] => 2020-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14361
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17439921
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/439921 | EXPRESSION CONSTRUCTS FOR THE GENETIC MODIFICATION OF CELLS | Mar 16, 2020 | Pending |
Array
(
[id] => 17664111
[patent_doc_number] => 11357787
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-06-14
[patent_title] => Method for selecting cells, method for producing nucleic acid, method for producing recombinant cells, method for producing target substance, method for producing pharmaceutical composition, and reagent
[patent_app_type] => utility
[patent_app_number] => 17/431268
[patent_app_country] => US
[patent_app_date] => 2020-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 10
[patent_no_of_words] => 13877
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 229
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17431268
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/431268 | Method for selecting cells, method for producing nucleic acid, method for producing recombinant cells, method for producing target substance, method for producing pharmaceutical composition, and reagent | Feb 16, 2020 | Issued |